A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States.

ABSTRACT:

Background

Copanlisib was recently granted accelerated approval by the FDA for the treatment of adult patients with relapsed follicular lymphoma (FL) after 2 previous systemic therapies. It is important to assess the effect that this and other changes in the treatment landscape of relapsed FL have on a payer's budget to inform formulary decisions.

Objective

To assess the budget impact associated with the addition of copanlisib to a formulary as third- or higher-line treatment for adult patients with relapsed FL who have received at least 2 previous systemic therapies, from the perspective of a U.S. third-party payer.

Methods

A budget impact model was developed over a 1-year horizon. The model considered a hypothetical population of 1 million people enrolled in a comme

SUBMITTER: Appukkuttan S 

PROVIDER: S-EPMC10398118 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature